The goal of the Oxford Experimental Cancer Medicine (ECMC) GCP laboratories is to accelerate the development of new cancer treatments by establishing validated assays for cancer biomarkers that can be used to evaluate clinical utility.
Our aim is to describe the distribution and prognostic impact of markers in patient sample collections and evaluate their predictive potential in clinical trials. In order to deliver GCP compliance over the whole translational research process we collaborate with research groups to develop protocols that will produce samples of optimum quality for analysis in validated assays.
Our main areas of biomarker development and validation include tumour marker analysis by automated immnohistochemical staining, and analysis of circulating biomarkers using ELISA. Other studies include western blot analysis of cell signalling proteins and fluorometric detection of drug analytes.
We work with small phase 1/2 clinical trials and larger phase 3 studies and collaborate with groups to either carry out the whole study from development through to analysis of the trial samples, or to provide training on the use of the facilities for translational work.
Liu S et al. Cancer 2015 121:202 Towards operative in vivo fluorescence imaging of c-Met proto-oncogene for personalization of therapy in ovarian cancer
Dr Sarah Blagden, Associate Professor of Experimental Cancer Therapeutics in the Department of Oncology, is the Experimental Cancer Medicine Centre (ECMC) lead for Oxford. She brings a wealth of experience to her role as Oxford ECMC lead; following training in Cambridge and the Royal Marsden she went on to become Director of Imperial’s Early Cancer Trials Unit before joining Oxford in the Department of Oncology in 2015. Sarah has an outstanding international reputation and brings with her to Oxford ECMC many specialist skills as a clinician scientist. It is this experience in both academic and commercial early phase trials, alongside her leadership and vision, that will ensure the world-leading translational work in cancer here in Oxford continues to thrive.